HOME >> MEDICINE >> NEWS
MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology

St. Louis, MO, May 31, 2001--MetaPhore Pharmaceuticals, Inc. today announced that it has received FDA approval of its Investigational New Drug (IND) application to conduct clinical trials in the U.S. to evaluate M40403, one of its enzyme mimetic compounds.

MetaPhore has initiated a Phase I study to test the safety and tolerability and to determine the pharmacokinetics of the compound in normal, healthy human subjects, as a precursor to Phase II trials in which M40403 will be tested as a co-therapy with interleukin-2 (IL-2) for advanced skin and end-stage kidney cancers. This study is the first human clinical trial for MetaPhore and the companys proprietary family of enzyme mimetic compounds that effectively mimic the action of one of the bodys primary free-radical fighting mechanisms, the natural enzyme superoxide dismutase (SOD).

In addition to cancer, MetaPhore is developing these compounds as drug candidates for pain and other diseases and conditions that have been associated with free-radical damage to tissues and cells.

The opening of this IND marks a major step for MetaPhore and our SOD enzyme mimetic program. For many years, we have understood the free-radical fighting power of the bodys natural SOD enzymes, but only recently have we been able to reproduce that benefit in a stable and selective drug form, said Denis Forster, Chief Operating Officer of MetaPhore. These novel therapeutics have tremendous potential, based on the growing body of research linking free-radical mediated damage with a wide range of acute and chronic disease states.

Preclinical studies in animals, including several recently presented at the American Association for Cancer Research at the end of March, have shown that M40403 significantly improves the effectiveness of IL-2, an approved treatment for inoperable metastatic melanoma and metastatic renal-cell carcinoma. Approximately 80,000 cases of melanoma and renal-cell carcinoma are diagnosed in th
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
30-May-2001


Page: 1 2 3

Related medicine news :

1. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
2. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. Pharmaceuticals and personal care products
6. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. NIAID initiates trial of experimental avian flu vaccine
11. American Academy of Neurology initiates health literacy training for neurologists

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2019)... (PRWEB) , ... February 13, 2019 , ... With Valentine’s ... sexually transmitted disease (STD) testing service, is sharing 7 tips to ensure ‘Safe Sex’: ... especially if you’re going to engage in safe sex. Having clear, open, and honest ...
(Date:2/13/2019)... , ... February 13, 2019 , ... Infertility is an issue for 1 in 6 ... A startling 2017 study outlining the sharp decline in male sperm count over the last ... , garnering worldwide attention and causing panic that we are in the midst of a ...
(Date:2/13/2019)... Ill. (PRWEB) , ... February 13, 2019 , ... Surgery ... significantly effective and safe treatment for obstructive sleep apnea (OSA), resulting in benefits that ... cardiovascular risk, according to a new study. , MMA should be regarded as the ...
(Date:2/12/2019)... ... February 12, 2019 , ... ... consulting organization, devoted to helping hospital leaders, staff, and physicians achieve excellence, ... . The website now features a streamlined design, improved functionality, and robust ...
(Date:2/12/2019)... ... February 12, 2019 , ... Surgical Theater is ... satisfaction, improve patient retention, and reduce patient outmigration for attendees of the Healthcare ... provides Surgical Theater with a great venue to highlight the value of patient ...
Breaking Medicine News(10 mins):
(Date:2/13/2019)... ... 2019 , ... Sensible Surrogacy today has launched a new ... couples who are unable to afford the staggering cost of surrogacy in the ... America or Eastern Europe for legal and secure surrogacy procedures. However North American ...
(Date:2/13/2019)... ... February 13, 2019 , ... Wound Care centers across the ... EHR software as an app inside their hospital’s EHR, substantially improving continuity of ... (electronic health record) pioneer, will soon launch its award-winning software as an “app” ...
(Date:2/13/2019)... ... February 13, 2019 , ... Abu Dhabi ... Private Partnership (PPP) between the Department of Health-Abu Dhabi (DoH) and Injazat Data ... Information Exchange system (HIE), a centralized platform to streamline healthcare connectivity for the ...
Breaking Medicine Technology:
Cached News: